News | July 02, 2024
Merck and Orion announce option providing Merck global exclusive rights to Opevesostat
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
Merck shared updates on the company’s oncology pipeline and focused R&D approach
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
Subscribe To Our Newsletter & Stay Updated
